Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of MK-4830 Alone and With Pembrolizumab in Advanced Solid Tumors (Japan)
jRCT2031210025Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of mk-4830 in Nonhematologic neoplasms, pancreatic adenocarcinoma (PDAC), glioblastoma (GBM) and 6 more (12 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicities in dose escalation and Arms G and H, Adverse events and 2 more. Started Jun 2021; status: completed.
02
Drugs
mk-4830
03
Conditions
Nonhematologic neoplasmspancreatic adenocarcinoma (PDAC)glioblastoma (GBM)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031210025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210025.